Floatz logo

CAFFEINE

Leukemia, Myeloid, Acute

CelgeneSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Leukemia, Myeloid, Acute cohort.

Asset / SponsorPhaseRating
Pevonedistat
University of Leipzig
Phase 3BB
bi 6727
Boehringer Ingelheim
Phase 3BB
Azacitidine
University of Colorado, Denver
Phase 2BB
Naxtarubicin
Moleculin Biotech, Inc.
Phase 2/3BB
TALACOTUZUMAB
GWT-TUD GmbH
Phase 2/3B

View all 50 →

Same molecule, other indications

CAFFEINE is also rated in:

migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
Carcinoma, Renal CellDormant
BB
Indicative ·
70 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →